• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Janux Therapeutics, Inc. - Common Stock (NQ:JANX)

    14.99 +1.72 (+12.95%)
    Streaming Delayed Price Updated: 3:28 PM EST, Jan 22, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,456,576
    Open 13.79
    Bid (Size) 14.98 (500)
    Ask (Size) 14.99 (200)
    Prev. Close 13.27
    Today's Range 13.46 - 15.28
    52wk Range 12.80 - 47.58
    Shares Outstanding 41,833,315
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb ↗
    Via Stocktwits
    News headline image
    Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors
    From Janux Therapeutics
    Via Business Wire

    Performance

    YTD
    +9.8%
    +9.8%
    1 Month
    +6.4%
    +6.4%
    3 Month
    -43.1%
    -43.1%
    6 Month
    -43.4%
    -43.4%
    1 Year
    -63.4%
    -63.4%

    More News

    Read More
    News headline image
    Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study
    From Janux Therapeutics
    Via Business Wire
    News headline image
    Options Exercise: Janux Executive Sells 16,665 Shares for $501,000 ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Which stocks are moving on Tuesday? ↗
    Via Chartmill
    News headline image
    Top movers analysis in the middle of the day on 2025-12-02: top gainers and losers in today's session. ↗
    Via Chartmill
    News headline image
    Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound ↗
    Via Stocktwits
    News headline image
    Which stocks are gapping on Tuesday? ↗
    Via Chartmill
    News headline image
    Janux Therapeutics Craters 50% On Prostate Cancer Update; Is It An 'Overreaction'? ↗
    Via Investor's Business Daily
    News headline image
    These stocks are moving in today's pre-market session ↗
    Via Chartmill
    News headline image
    What's going on in today's after hours session ↗
    Via Chartmill
    News headline image
    Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
    From Janux Therapeutics
    Via Business Wire
    News headline image
    Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC
    From Janux Therapeutics
    Via Business Wire
    News headline image
    Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
    From Janux Therapeutics
    Via Business Wire
    News headline image
    Janux (JANX) R&D Soars Revenue Misses ↗
    Via The Motley Fool
    News headline image
    Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
    From Janux Therapeutics
    Via Business Wire
    News headline image
    Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck
    From Janux Therapeutics
    Via Business Wire
    News headline image
    Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day
    From Janux Therapeutics
    Via Business Wire
    News headline image
    Janux Therapeutics to Host Virtual R&D Day on July 24, 2025
    From Janux Therapeutics
    Via Business Wire
    News headline image
    10 Health Care Stocks Whale Activity In Today's Session ↗
    Via Benzinga
    News headline image
    This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
    Via Benzinga
    News headline image
    Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
    From Janux Therapeutics
    Via Business Wire
    News headline image
    Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
    From Janux Therapeutics
    Via Business Wire
    News headline image
    Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates
    From Janux Therapeutics
    Via Business Wire
    News headline image
    Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
    From Janux Therapeutics
    Via Business Wire

    Frequently Asked Questions

    Is Janux Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Janux Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Janux Therapeutics, Inc. - Common Stock trade on?
    Janux Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Janux Therapeutics, Inc. - Common Stock?
    The ticker symbol for Janux Therapeutics, Inc. - Common Stock is JANX on the Nasdaq Stock Market
    What is the current price of Janux Therapeutics, Inc. - Common Stock?
    The current price of Janux Therapeutics, Inc. - Common Stock is 14.99
    When was Janux Therapeutics, Inc. - Common Stock last traded?
    The last trade of Janux Therapeutics, Inc. - Common Stock was at 01/22/26 03:28 PM ET
    What is the market capitalization of Janux Therapeutics, Inc. - Common Stock?
    The market capitalization of Janux Therapeutics, Inc. - Common Stock is 627.04M
    How many shares of Janux Therapeutics, Inc. - Common Stock are outstanding?
    Janux Therapeutics, Inc. - Common Stock has 627M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.